<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575610</url>
  </required_header>
  <id_info>
    <org_study_id>2000028042</org_study_id>
    <nct_id>NCT04575610</nct_id>
  </id_info>
  <brief_title>IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)</brief_title>
  <official_title>Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of PF-06650833 in addition to
      standard-of-care compared to standard-of-care treatment alone in improving outcomes in
      patients with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proposed is a randomized, double-blind, placebo-controlled, parallel group Phase 2 study of
      the efficacy and safety of PF-06650833, an investigational drug, in hospitalized adult male
      and female patients with SARS-CoV-2-induced ARDS who need mechanical ventilation.

      The primary objective of this study is to assess the efficacy of PF-06650833 in addition to
      standard-of-care compared to standard-of-care treatment alone in improving outcomes in
      patients with COVID-19, evidence of increased inflammation, and ARDS requiring mechanical
      ventilation or extracorporeal membrane oxygenation at time of admission.

      The secondary objectives of this study are to evaluate:

        1. Proportion of patients alive, extubated, and receiving no more that low flow oxygen
           supplementation by nasal cannula or face mask (excluding extubation for compassionate
           purposes in terminal patients). This would correspond to an at least 2-point improvement
           in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale (1 =
           non hospitalized, no limitations on activity, and 8 = death) at Days 29 and 61

        2. Proportion of patients alive, extubated, and receiving any level oxygen supplementation,
           including non-invasive positive pressure ventilation or high flow oxygen device
           (excluding extubation for compassionate purposes in terminal patients). This would
           correspond to an at least 1-point improvement in the NIAID ordinal scale (1 = non
           hospitalized, no limitations on activity, and 8 = death) at Days 29 and 61

        3. Percentage of patients in each category of the NIAID 8-point ordinal scale of disease
           severity (Days 8, 15, 22, 29, and 61). The ordinal scale is an assessment of the
           clinical status at the first assessment of a given study day. The scale is as follows:

             -  Not hospitalized, no limitations on activities;

             -  Not hospitalized, limitation on activities and/or requiring home oxygen*

             -  Hospitalized, not requiring supplemental oxygen* - no longer requires ongoing
                medical care

             -  Hospitalized, not requiring supplemental oxygen* - requiring ongoing medical care
                (COVID-19 related or otherwise)

             -  Hospitalized, requiring supplemental oxygen*;

             -  Hospitalized, on non-invasive ventilation (NIV)** or high flow oxygen device;

             -  Hospitalized, on invasive mechanical ventilation or ECMO;

             -  Death

                  -  For patients on chronic home O2 supplementation, supplemental O2 is defined as
                     &gt;= home O2 requirement.

                       -  Use of NIV for chronic conditions [e.g. Obstructive sleep apnea (OSA)] is
                          not applicable

        4. Mortality rate at Day 61

        5. Time to a 1-point improvement in the NIAID 8-point ordinal scale of disease severity

        6. Time to a 2-point improvement in the NIAID 8-point ordinal scale of disease severity

        7. Change from baseline in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and

        8. Arterial partial pressure of oxygen (PaO2) / Fractional concentration of inspired oxygen
           (FiO2) ratio (or P/F ratio)

        9. Change of the Sequential Organ Failure Assessment (SOFA). The SOFA evaluates 6
           variables, each representing an organ system (one for the respiratory, cardiovascular,
           hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4
           (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.

       10. Duration (days) of mechanical ventilation

       11. Ventilator free days

       12. Safety as assessed by reporting of adverse events (AEs), changes in clinical laboratory
           parameters (e.g., haemoglobin (Hb), white blood cell (WBC) count, platelets, hepatic
           transaminases, bilirubin, serum creatinine)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality at Day 29</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>All-cause mortality at Day 29 (end of planned treatment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2 point decrease in the NIAID ordinal scale. The NIAID scale is as follows:
Not hospitalized, no limitations on activities
Not hospitalized, limitations on activities and/or requiring home oxygen
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
Hospitalized, requiring supplemental oxygen
Hospitalized, on non-invasive ventilation or high-flow oxygen devices
Hospitalized, on invasive mechanical ventilation or ECMO
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>61 days</time_frame>
    <description>Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2 point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>61 days</time_frame>
    <description>Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>8 days</time_frame>
    <description>Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 8. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>15 days</time_frame>
    <description>Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 15. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>22 days</time_frame>
    <description>Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 22. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 29. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>61 days</time_frame>
    <description>Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 61. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>61 days</time_frame>
    <description>Mortality rate at day 61</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Time to a 1-point decrease in the NIAID 8-point ordinal scale of disease severity (1 = not hospitalized, no limitations on activities, and 8 = death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Time to a 2-point decrease in the NIAID 8-point ordinal scale of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>3 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>5 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>11 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>15 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>22 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity (8 point scale)</measure>
    <time_frame>29 days</time_frame>
    <description>Change from baseline in the ordinal scale from Day 1 to Days 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the SOFA score.</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>The SOFA evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of mechanical ventilation</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>The duration is days spent on mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days.</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>The number of days hospitalized not on a ventilator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>PF-06650833 + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). All dosing of PF-06650833 will be in addition to current hospital SOC therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo tablets will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06650833</intervention_name>
    <description>Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.</description>
    <arm_group_label>PF-06650833 + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets will be administered.</description>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Adult male and female patients, including women of childbearing potential, at least 18
             years of age, inclusive

          2. Participant (or legally authorized representative) capable of giving signed informed
             consent

          3. Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection

          4. Clinical findings and an imaging study consistent with ARDS;

          5. PaO2 / FiO2 ratio &lt; 300;

          6. A requirement for mechanical ventilation â‰¤ 48 hours prior to enrollment.

          7. Evidence of increased inflammation as assessed by hsCRP &gt; ULN AND at least ONE of the
             following being &gt; upper limit of normal (as available):

               1. ferritin

               2. procalcitonin

               3. D-dimer

               4. fibrinogen

               5. LDH

               6. PT/PTT

        EXCLUSION CRITERIA

          1. Suspected or known active systemic bacterial, viral (except SARS-CoV2 infection), or
             fungal infections

          2. Active herpes zoster infection

          3. Known active or latent tuberculosis (TB) or history of inadequately treated TB

          4. Active hepatitis B or hepatitis C

          5. Known history of human immunodeficiency virus (HIV) infection with a detectable viral
             load or CD4 count &lt; 500 cells / mm3 (patients for whom documented viral load or CD4
             counts are available will be excluded)

          6. Active hematologic cancer

          7. Metastatic or intractable cancer

          8. Pre-existing neurodegenerative disease

          9. Severe hepatic impairment defined as Child-Pugh Class B or Class C at baseline

         10. Severe renal impairment with an estimated glomerular filtration rate (eGFR) &lt; 45
             mL/min/1.73 m2

         11. Severe anemia (Hb &lt; 8.0 g/dL)

         12. Any of the following abnormal laboratory values:

               1. absolute lymphocyte count &lt;250 cells/mm3

               2. absolute neutrophil Count (ANC) &lt;1000 cells/mm3

               3. Platelet count &lt;50,000 cells/mm3

               4. ALT or AST &gt; 5X ULN, or other evidence of hepatocellular synthetic dysfunction or
                  total bilirubin &gt; 2X ULN

         13. Any other medical condition or laboratory abnormality that may increase the risk of
             study participation or, in the investigator's judgment, make the participant
             inappropriate for the study

         14. Prohibited concomitant therapy (see section 1.12.7.2)

         15. Pregnancy (a negative urine or serum pregnancy test is required for inclusion)

         16. Immunocompromised patients, patients with known immunodeficiencies or taking potent
             immunosuppressive agents (e.g., azathioprine, cyclosporine)

         17. Anticipated survival &lt; 72 hours as assessed by the Investigator.

         18. Participation in other clinical trials of investigational treatments for COVID-19

         19. Known history of nephrolithiasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Chun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyung Chun, MD</last_name>
    <phone>650-704-8383</phone>
    <email>hyung.chun@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Borges, MS, BS</last_name>
    <phone>203-737-2737</phone>
    <email>kelly.borges@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyung Chun, MD</last_name>
      <email>hyung.chun@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Borges, MS, BS</last_name>
      <email>kelly.borges@yale.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Hyung Chun</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Protein Kinase Inhibitors</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

